Genmab: Darzalex Growth Fuels Rally, Upside Is Tight [Seeking Alpha]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Seeking Alpha
In my view, the key driver of increased investor interest in Genmab is the strong performance of anti-cancer medications developed jointly with J&J. So, sales of Darzalex, the multiple myeloma blockbuster, amounted to $3.9 billion in Q4, up 26.6% year-on-year. However, due to the acquisition of Merus, the limited upside relative to Wall Street analysts' price target, and the expiration of Darzalex's US exclusivity in 2029, I believe Genmab's risk/reward is currently balanced. South_agency/E+ via Getty Images Genmab ( GMAB ) is becoming a prominent player in the cancer and multiple sclerosis therapeutics markets. It is thanks to Kesimpta, Epkinly , and Talvey/Darzalex, which were developed jointly with Novartis ( NVS ), AbbVie ( This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) [Yahoo! Finance]Yahoo! Finance
- Grant of Restricted Stock Units and Warrants to Employees in Genmab [Yahoo! Finance]Yahoo! Finance
- Genmab A/S (NASDAQ:GMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $39.00 price target on the stock.MarketBeat
- Genmab (CPSE:GMAB) Valuation Check After Epcoritamab Trial Update And DARZALEX Royalty Momentum [Yahoo! Finance]Yahoo! Finance
- Genmab (GMAB)'s Future Potential Underappreciated by Market [Yahoo! Finance]Yahoo! Finance